CU20140023A7 - DERIVADOS DE N-(3-(1,2,4-OXADIAZOL-3/5-IL)FENIL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA QUINASA c-Kit - Google Patents

DERIVADOS DE N-(3-(1,2,4-OXADIAZOL-3/5-IL)FENIL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA QUINASA c-Kit

Info

Publication number
CU20140023A7
CU20140023A7 CUP2014000023A CU20140023A CU20140023A7 CU 20140023 A7 CU20140023 A7 CU 20140023A7 CU P2014000023 A CUP2014000023 A CU P2014000023A CU 20140023 A CU20140023 A CU 20140023A CU 20140023 A7 CU20140023 A7 CU 20140023A7
Authority
CU
Cuba
Prior art keywords
kit
inhibitors
piridin
oxadiazol
imidazo
Prior art date
Application number
CUP2014000023A
Other languages
English (en)
Inventor
Vince Yeh
Xiaolin Li
Xiaodong Liu
Jon Loren
Valentina Molteni
Juliet Nabakka
Bao Nguyen
Hank Michael James Petrassi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20140023A7 publication Critical patent/CU20140023A7/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona compuestos y composiciones farmacéuticas de los mismos, los cuales son útiles como inhibidores de las proteínas quinasas, así como también métodos para utilizar tales compuestos y así tratar, aliviar o prevenir una condición asociada con actividad anormal o desregulada de las quinasas. En algunas realizaciones, la invención proporciona métodos para utilizar tales compuestos para tratar, aliviar o prevenir enfermedades o trastornos que involucran activación anormal de la c- kit o quinasas c- kit y PDGFR (PDGFRalfa, PDGFRbeta).
CUP2014000023A 2011-09-01 2014-02-27 DERIVADOS DE N-(3-(1,2,4-OXADIAZOL-3/5-IL)FENIL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA QUINASA c-Kit CU20140023A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530028P 2011-09-01 2011-09-01
PCT/US2012/052621 WO2013033070A1 (en) 2011-09-01 2012-08-28 COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
CU20140023A7 true CU20140023A7 (es) 2014-04-24

Family

ID=46829898

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2014000023A CU20140023A7 (es) 2011-09-01 2014-02-27 DERIVADOS DE N-(3-(1,2,4-OXADIAZOL-3/5-IL)FENIL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA QUINASA c-Kit

Country Status (42)

Country Link
US (1) US9199981B2 (es)
EP (1) EP2751102B1 (es)
JP (1) JP6117208B2 (es)
KR (1) KR101959590B1 (es)
CN (1) CN103764653B (es)
AP (1) AP2014007494A0 (es)
AR (1) AR087752A1 (es)
AU (1) AU2012300248B2 (es)
BR (1) BR112014004504B1 (es)
CA (1) CA2845159C (es)
CL (1) CL2014000494A1 (es)
CO (1) CO6900140A2 (es)
CR (1) CR20140106A (es)
CU (1) CU20140023A7 (es)
CY (1) CY1121695T1 (es)
DK (1) DK2751102T3 (es)
EA (1) EA024293B1 (es)
ES (1) ES2732671T3 (es)
GT (1) GT201400036A (es)
HR (1) HRP20191140T1 (es)
HU (1) HUE044373T2 (es)
IL (1) IL231226A (es)
JO (1) JOP20120246B1 (es)
LT (1) LT2751102T (es)
MA (1) MA35459B1 (es)
ME (1) ME03395B (es)
MX (1) MX342329B (es)
MY (1) MY167245A (es)
PE (1) PE20141033A1 (es)
PH (1) PH12014500351B1 (es)
PL (1) PL2751102T3 (es)
PT (1) PT2751102T (es)
RS (1) RS59025B1 (es)
SG (1) SG2014011050A (es)
SI (1) SI2751102T1 (es)
TN (1) TN2014000061A1 (es)
TR (1) TR201909189T4 (es)
TW (1) TWI543981B (es)
UA (1) UA110841C2 (es)
UY (1) UY34300A (es)
WO (1) WO2013033070A1 (es)
ZA (1) ZA201401113B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2751104B1 (en) 2011-09-01 2019-09-25 Novartis AG Compounds and compositions as c-kit kinase inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
CN104619709B (zh) * 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
ES2675720T3 (es) 2013-01-10 2018-07-12 Pulmokine, Inc. Inhibidores de quinasa no selectivos
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
US9925184B2 (en) 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
WO2015082411A1 (de) * 2013-12-05 2015-06-11 Bayer Pharma Aktiengesellschaft Aryl- und hetaryl-substituierte imidazo[1,2-a]pyridin-3-carboxamide und ihre verwendung
CN103965190A (zh) * 2014-05-20 2014-08-06 定陶县友帮化工有限公司 一种咪唑并[1,2-a]吡啶-3-甲酸的合成方法
BR112017028318B1 (pt) 2015-07-02 2024-02-20 Janssen Sciences Ireland Uc Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação
US10059708B2 (en) * 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
BR112018076126A2 (pt) 2016-06-16 2019-03-26 Janssen Sciences Ireland Unlimited Company compostos heterocíclicos como antibacterianos
MX2018015657A (es) 2016-06-16 2019-03-14 Janssen Sciences Ireland Unlimited Co Compuestos heterociclico como antibacterianos.
CA3041679A1 (en) 2016-10-27 2018-05-03 Lawrence S. ZISMAN Combination therapy for treating pulmonary hypertension
EP4417262A3 (en) 2017-03-01 2024-11-27 Janssen Sciences Ireland Unlimited Company Combination therapy
CN111039946A (zh) * 2018-10-15 2020-04-21 上海轶诺药业有限公司 一类咪唑并芳环类化合物的制备和应用
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114096538A (zh) * 2019-05-13 2022-02-25 诺华股份有限公司 N-(5-(5-((1r,2s)-2-氟环丙基)-1,2,4-噁二唑-3-基)-2-甲基苯基)咪唑并[1,2-a]吡啶-3-甲酰胺的结晶型
WO2021048342A1 (en) 2019-09-13 2021-03-18 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021187486A1 (ja) * 2020-03-17 2021-09-23 大日本住友製薬株式会社 オキサジアゾール誘導体
WO2022016021A1 (en) * 2020-07-15 2022-01-20 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
EP4247368A4 (en) * 2020-11-19 2024-10-23 Third Harmonic Bio, Inc. PHARMACEUTICAL COMPOSITIONS OF A SELECTIVE C-KIT KINASE INHIBITOR AND METHODS FOR THE PREPARATION AND USE THEREOF
US20220175740A1 (en) * 2020-11-19 2022-06-09 Novartis Ag Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
WO2022182982A1 (en) * 2021-02-26 2022-09-01 Third Harmonic Bio, Inc. Methods for treating c-kit kinase mediated diseases and disorders using a selective c-kit kinase inhibitor
EP4308239A1 (en) 2021-03-16 2024-01-24 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CN117440958A (zh) * 2021-03-17 2024-01-23 爱尔兰詹森科学公司 抗菌化合物
MX2023010948A (es) 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
IL312366A (en) 2021-10-28 2024-06-01 Janssen Sciences Ireland Unlimited Co Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
IL321144A (en) 2022-11-30 2025-07-01 Blueprint Medicines Corp History of N-phenyl-pyrazolo[5,1-A]pyridine-3-carboxamide as wild-type C-KIT kinase inhibitors for the treatment of erectile dysfunction
WO2024123966A1 (en) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
CN120659784A (zh) * 2022-12-07 2025-09-16 第三谐波生物股份有限公司 作为c-Kit激酶抑制剂的化合物和组合物
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
US20250042898A1 (en) * 2023-07-25 2025-02-06 Enanta Pharmaceuticals, Inc. Pharmaceutical Compounds And Compositions As c-Kit Kinase Inhibitors
TW202523302A (zh) 2023-11-02 2025-06-16 美商阿克思生物科學有限公司 噻唑化合物及其使用方法
TW202542157A (zh) * 2024-01-04 2025-11-01 大陸商上海翰森生物醫藥科技有限公司 多環類衍生物抑制劑、其製備方法和應用
WO2025256552A1 (zh) * 2024-06-11 2025-12-18 上海翰森生物医药科技有限公司 吡唑类衍生物抑制剂、其制备方法和应用
WO2025256609A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
WO2025259929A1 (en) * 2024-06-13 2025-12-18 Third Harmonic Bio, Inc. COMPOUNDS AND COMPOSITIONS AS c-Kit KINASE INHIBITORS
CN121181581A (zh) * 2024-06-21 2025-12-23 上海美悦生物科技发展有限公司 一种稠杂环化合物、其制备方法和用途
CN121426815A (zh) * 2024-07-30 2026-01-30 上海美悦生物科技发展有限公司 一种杂环化合物、其制备方法和用途
WO2026032333A1 (zh) * 2024-08-06 2026-02-12 上海美悦生物科技发展有限公司 一种杂环化合物、其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518993D0 (en) * 1995-09-16 1995-11-15 Agrevo Uk Ltd Fungicides
US20070072861A1 (en) * 2000-03-27 2007-03-29 Barbara Roniker Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
AU2003251561A1 (en) 2002-06-20 2004-01-06 Beacon Looms, Inc. Knitted electrical conductor fabric
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
BRPI0718677A2 (pt) 2006-11-03 2013-11-26 Irm Llc Compostos e composições como inibidores de quinases proteicas
AU2011329233A1 (en) * 2010-11-15 2013-05-23 Abbvie Deutschland Gmbh & Co Kg NAMPT and ROCK inhibitors
JP2014525450A (ja) * 2011-09-01 2014-09-29 アイアールエム・リミテッド・ライアビリティ・カンパニー c−Kitキナーゼ阻害剤としての化合物および組成物
EA201490537A1 (ru) * 2011-09-01 2014-07-30 АйАрЭм ЭлЭлСи СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ C-Kit
EP2751104B1 (en) * 2011-09-01 2019-09-25 Novartis AG Compounds and compositions as c-kit kinase inhibitors

Also Published As

Publication number Publication date
PH12014500351A1 (en) 2014-04-07
UY34300A (es) 2013-04-05
JOP20120246B1 (ar) 2022-03-14
TR201909189T4 (tr) 2019-07-22
CA2845159C (en) 2020-11-03
SG2014011050A (en) 2014-08-28
SI2751102T1 (sl) 2019-08-30
EP2751102B1 (en) 2019-03-27
ZA201401113B (en) 2015-10-28
MX2014002482A (es) 2014-11-25
MA35459B1 (fr) 2014-09-01
ME03395B (me) 2020-01-20
AU2012300248A1 (en) 2014-04-17
AR087752A1 (es) 2014-04-16
LT2751102T (lt) 2019-07-10
AU2012300248B2 (en) 2015-08-27
US9199981B2 (en) 2015-12-01
DK2751102T3 (da) 2019-07-01
KR20140071382A (ko) 2014-06-11
TN2014000061A1 (en) 2015-07-01
HRP20191140T1 (hr) 2019-09-20
JP2014525444A (ja) 2014-09-29
CY1121695T1 (el) 2020-07-31
EA201490540A1 (ru) 2014-06-30
ES2732671T3 (es) 2019-11-25
BR112014004504B1 (pt) 2022-03-22
AP2014007494A0 (en) 2014-03-31
EA024293B1 (ru) 2016-09-30
EP2751102A1 (en) 2014-07-09
IL231226A0 (en) 2014-04-30
MY167245A (en) 2018-08-14
CN103764653B (zh) 2015-12-02
CR20140106A (es) 2014-05-02
NZ621092A (en) 2016-06-24
IL231226A (en) 2017-03-30
CN103764653A (zh) 2014-04-30
HUE044373T2 (hu) 2019-10-28
GT201400036A (es) 2015-06-02
TW201313716A (zh) 2013-04-01
MX342329B (es) 2016-09-26
BR112014004504A2 (pt) 2017-03-28
PH12014500351B1 (en) 2019-04-03
PT2751102T (pt) 2019-07-10
CA2845159A1 (en) 2013-03-07
PL2751102T3 (pl) 2019-09-30
PE20141033A1 (es) 2014-08-30
KR101959590B1 (ko) 2019-03-18
UA110841C2 (uk) 2016-02-25
JP6117208B2 (ja) 2017-04-19
CO6900140A2 (es) 2014-03-20
RS59025B1 (sr) 2019-08-30
TWI543981B (zh) 2016-08-01
CL2014000494A1 (es) 2014-09-05
US20130059846A1 (en) 2013-03-07
WO2013033070A1 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
CU20140023A7 (es) DERIVADOS DE N-(3-(1,2,4-OXADIAZOL-3/5-IL)FENIL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA QUINASA c-Kit
CU20140024A7 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
EA201490542A1 (ru) Соединения и композиции в качестве pdgfr киназных ингибиторов
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
EA201001331A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-kit И PDGFR
EA201490537A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ C-Kit
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
BR112014003963A2 (pt) compostos e composições como inibidores de quinase c-kit
CR10670A (es) Compuestos y composiciones como inhibidores de la proteina quinasa
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
ECSP099378A (es) Compuestos y composiciones como inhibidores de la proteina quinasa
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
EA200901483A1 (ru) ПРОИЗВОДНЫЕ ПИРИМИДИНА И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
MX382991B (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
MX386542B (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
HK1203852A1 (zh) 具有激酶抑制活性的二苯基甲醇-吡唑衍生物及其用途
EA201390519A1 (ru) Замещенные соединения пиридазинкарбоксамида в качестве киназных ингибиторов